Yuchao Xie1, Mitchell R McGill1, Kenneth Dorko1, Sean C Kumer2, Timothy M Schmitt2, Jameson Forster2, Hartmut Jaeschke3. 1. Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA. 2. Department of Surgery, University of Kansas Medical Center, Kansas City, KS 66160, USA. 3. Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA. Electronic address: hjaeschke@kumc.edu.
Abstract
UNLABELLED: Acetaminophen (APAP) overdose is the most prevalent cause of drug-induced liver injury in western countries. Numerous studies have been conducted to investigate the mechanisms of injury after APAP overdose in various animal models; however, the importance of these mechanisms for humans remains unclear. Here we investigated APAP hepatotoxicity using freshly isolated primary human hepatocytes (PHH) from either donor livers or liver resections. PHH were exposed to 5mM, 10mM or 20mM APAP over a period of 48 h and multiple parameters were assessed. APAP dose-dependently induced significant hepatocyte necrosis starting from 24h, which correlated with the clinical onset of human liver injury after APAP overdose. Interestingly, cellular glutathione was depleted rapidly during the first 3h. APAP also resulted in early formation of APAP-protein adducts (measured in whole cell lysate and in mitochondria) and mitochondrial dysfunction, indicated by the loss of mitochondrial membrane potential after 12h. Furthermore, APAP time-dependently triggered c-Jun N-terminal kinase (JNK) activation in the cytosol and translocation of phospho-JNK to the mitochondria. Both co-treatment and post-treatment (3h) with the JNK inhibitor SP600125 reduced JNK activation and significantly attenuated cell death at 24h and 48h after APAP. The clinical antidote N-acetylcysteine offered almost complete protection even if administered 6h after APAP and a partial protection when given at 15 h. CONCLUSION: These data highlight important mechanistic events in APAP toxicity in PHH and indicate a critical role of JNK in the progression of injury after APAP in humans. The JNK pathway may represent a therapeutic target in the clinic.
UNLABELLED: Acetaminophen (APAP) overdose is the most prevalent cause of drug-induced liver injury in western countries. Numerous studies have been conducted to investigate the mechanisms of injury after APAPoverdose in various animal models; however, the importance of these mechanisms for humans remains unclear. Here we investigated APAPhepatotoxicity using freshly isolated primary human hepatocytes (PHH) from either donor livers or liver resections. PHH were exposed to 5mM, 10mM or 20mM APAP over a period of 48 h and multiple parameters were assessed. APAP dose-dependently induced significant hepatocyte necrosis starting from 24h, which correlated with the clinical onset of humanliver injury after APAPoverdose. Interestingly, cellular glutathione was depleted rapidly during the first 3h. APAP also resulted in early formation of APAP-protein adducts (measured in whole cell lysate and in mitochondria) and mitochondrial dysfunction, indicated by the loss of mitochondrial membrane potential after 12h. Furthermore, APAP time-dependently triggered c-Jun N-terminal kinase (JNK) activation in the cytosol and translocation of phospho-JNK to the mitochondria. Both co-treatment and post-treatment (3h) with the JNK inhibitor SP600125 reduced JNK activation and significantly attenuated cell death at 24h and 48h after APAP. The clinical antidote N-acetylcysteine offered almost complete protection even if administered 6h after APAP and a partial protection when given at 15 h. CONCLUSION: These data highlight important mechanistic events in APAPtoxicity in PHH and indicate a critical role of JNK in the progression of injury after APAP in humans. The JNK pathway may represent a therapeutic target in the clinic.
Authors: Mitchell R McGill; Matthew R Sharpe; C David Williams; Mohammad Taha; Steven C Curry; Hartmut Jaeschke Journal: J Clin Invest Date: 2012-03-01 Impact factor: 14.808
Authors: Daniel J Antoine; Rosalind E Jenkins; James W Dear; Dominic P Williams; Mitchell R McGill; Matthew R Sharpe; Darren G Craig; Kenneth J Simpson; Hartmut Jaeschke; B Kevin Park Journal: J Hepatol Date: 2012-01-17 Impact factor: 25.083
Authors: Philip J Starkey Lewis; James Dear; Vivien Platt; Kenneth J Simpson; Darren G N Craig; Daniel J Antoine; Neil S French; Neeraj Dhaun; David J Webb; Eithne M Costello; John P Neoptolemos; Jonathan Moggs; Chris E Goldring; B Kevin Park Journal: Hepatology Date: 2011-11 Impact factor: 17.425
Authors: Mie Shinohara; Maria D Ybanez; Sanda Win; Tin Aung Than; Shilpa Jain; William A Gaarde; Derick Han; Neil Kaplowitz Journal: J Biol Chem Date: 2010-01-08 Impact factor: 5.157
Authors: Mitchell R McGill; Mengde Cao; Archie Svetlov; Matthew R Sharpe; C David Williams; Steven C Curry; Anwar Farhood; Hartmut Jaeschke; Stanislav I Svetlov Journal: Biomarkers Date: 2014-03-06 Impact factor: 2.658
Authors: Luqi Duan; John S Davis; Benjamin L Woolbright; Kuo Du; Mala Cahkraborty; James Weemhoff; Hartmut Jaeschke; Mohammed Bourdi Journal: Food Chem Toxicol Date: 2016-10-20 Impact factor: 6.023